Want to see SYRA full AI Analyst Report?
Syra Health Corp. Class A (SYRA) AI Stock Analysis
Syra Health Corp. Class A
(Other OTC:SYRA)
The score is primarily supported by improving financial performance (turnaround to modest profitability, strong TTM revenue growth, and currently low leverage) and a generally constructive technical trend (price above key moving averages). Offsetting these positives, valuation is a key risk factor (P/E ~100 with no dividend support) and profitability/cash flow remain thin and not yet clearly durable.
Syra Health Corp. Class A (SYRA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $10.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 24.66K
- Price to Earnings (P/E)
- 100.0
- Beta (1Y)
- 1.45
- Revenue Growth
- 0.32%
- EPS Growth
- ―
- Country
- US
- Employees
- 89
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Syra Health Corp. Class A Business Overview & Revenue Model
Company Description
Syra Health Corp. is a U.S.-based healthcare services company offering a diverse portfolio of solutions. Their core offerings span health education, population health management, behavioral and mental health support, healthcare workforce solutions, a...
How the Company Makes Money
Syra Health generates revenue primarily by providing healthcare-related services to organizations (such as healthcare providers, employers, and public-sector entities) under contracted engagements. Key revenue streams include (1) service fees from st...
Syra Health Corp. Class A Earnings Call Summary
The earnings call presented a mix of positive developments such as revenue growth in the Population Health unit and improved operational efficiencies, alongside challenges like NASDAQ delisting, federal contract delays, and a decline in Healthcare Workforce revenue. The balance of achievements and setbacks suggests a cautious outlook.
Q1-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the first quarter of 2025, Syra Health reported positive financial metrics, with total revenue reaching $1.9 million, reflecting a 6% annual growth compared to the same period in 2024. The company achieved a substantial gross margin expansion of 14.6 percentage points, reaching 31.7%, driven by the strong performance of its Population Health business unit, which contributed 65% of total revenue. This unit experienced a 261% year-over-year revenue increase, supported by new contracts and extensions. Despite a 39% reduction in operating expenses, Syra reported a net loss of $472,000, a significant improvement from the $1.4 million loss recorded in the first quarter of 2024. The company also highlighted a strategic shift towards higher-margin, recurring revenue streams and announced the voluntary delisting from NASDAQ to focus on core fundamentals. However, ongoing federal-level changes pose potential challenges, affecting revenue visibility and leading to the withdrawal of previous full-year guidance.
Syra Health Corp. Class A Financial Statement Overview
Summary
Financials show a near-term inflection with very strong TTM revenue growth and a return to small profitability, supported by improved gross margin and low current leverage. However, profitability remains thin (EBIT/EBITDA margins ~1.7%–1.8%) and cash flow consistency is not yet proven—FCF is only modestly positive after prior multi-year burn, and historical volatility (including earlier periods of strained capitalization) raises sustainability risk.
Income Statement
56NeutralBalance Sheet
70PositiveCash Flow
48Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.09M | 7.23M | 7.98M | 5.52M | 5.62M | 1.41M |
| Gross Profit | 3.18M | 2.49M | 1.65M | 1.41M | 1.06M | 430.35K |
| EBITDA | 146.26K | -862.60K | -3.68M | -2.84M | -2.07M | -3,073 |
| Net Income | 130.75K | -896.33K | -3.76M | -2.94M | -2.12M | -3,280 |
Balance Sheet | ||||||
| Total Assets | 3.83M | 2.77M | 3.68M | 4.92M | 2.32M | 536.89K |
| Cash, Cash Equivalents and Short-Term Investments | 2.12M | 1.61M | 2.40M | 3.28M | 3,344 | 100.01K |
| Total Debt | 149.34K | 143.79K | 452.08K | 248.10K | 934.84K | 342.86K |
| Total Liabilities | 1.20M | 674.74K | 800.76K | 910.07K | 1.61M | 544.04K |
| Stockholders Equity | 2.63M | 2.10M | 2.88M | 4.01M | 710.10K | -7,147 |
Cash Flow | ||||||
| Free Cash Flow | 109.58K | -447.85K | -2.94M | -2.77M | -2.37M | -94.49K |
| Operating Cash Flow | 109.68K | -447.75K | -2.93M | -2.76M | -2.24M | -88.20K |
| Investing Cash Flow | -107 | -107 | -11.11K | -15.25K | -121.26K | -6,289 |
| Financing Cash Flow | -291.75K | -332.82K | 2.06M | 6.05M | 2.27M | 191.50K |
Syra Health Corp. Class A Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRA, the sentiment is Positive. The current price of 0.90 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.87, and above the 200-day MA of 0.52, indicating a bullish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 54.36 is Neutral, neither overbought nor oversold. The STOCH value of 60.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRA.
Syra Health Corp. Class A Risk Analysis
Syra Health Corp. Class A disclosed 49 risk factors in its most recent earnings report. Syra Health Corp. Class A reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksSyra Health Corp. Class A Peers Comparison
Overall Rating
CON77Outperform
SGRY59Neutral- SYRA55Neutral
USPH52Neutral
DCGO43Neutral
AIRS41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CON | 77Outperform | $5.15B | 26.05 | 47.30% | 0.62% | 14.02% | 31.92% |
| SGRY | 59Neutral | $2.99B | -33.64 | -5.21% | ― | 3.99% | 51.58% |
| SYRA | 55Neutral | $12.78M | 100.00 | 5.62% | ― | 0.32% | ― |
| USPH | 52Neutral | $1.28B | 504.88 | -1.27% | 2.13% | 11.32% | -92.59% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| DCGO | 43Neutral | $24.44M | -0.13 | -115.58% | ― | -32.40% | -969.05% |
| AIRS | 41Neutral | $124.72M | -9.53 | -12.52% | ― | -8.71% | 26.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SYRA | Syra Health Corp. Class A | 0.90 | 0.83 | 1167.61% | |
| USPH | U.s. Physical Therapy | 85.83 | 1.09 | 1.28% | |
| SGRY | Surgery Partners Inc. | 23.21 | 1.51 | 6.96% | |
| DCGO | DocGo, Inc. | 0.25 | -0.78 | -76.12% | |
| AIRS | Airsculpt Technologies, Inc. | 1.73 | -8.66 | -83.35% | |
| CON | Concentra Group Holdings Parent, Inc. | 40.38 | 20.90 | 107.26% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026